Satellos Bioscience (NASDAQ:MSLE) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Satellos Bioscience (NASDAQ:MSLE) released its quarterly earnings data on Friday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.02), Zacks reports.

Satellos Bioscience Stock Performance

Shares of MSLE stock traded down $0.16 during trading hours on Friday, reaching $7.01. 43,311 shares of the company’s stock were exchanged, compared to its average volume of 38,248. Satellos Bioscience has a 1 year low of $4.53 and a 1 year high of $13.39. The stock has a market cap of $146.02 million, a PE ratio of -4.52 and a beta of 1.60. The firm has a fifty day moving average price of $7.52.

Analysts Set New Price Targets

Several research firms recently weighed in on MSLE. Leerink Partners began coverage on Satellos Bioscience in a report on Monday, April 6th. They issued an “outperform” rating and a $20.00 price objective for the company. Wall Street Zen downgraded shares of Satellos Bioscience from a “sell” rating to a “strong sell” rating in a report on Saturday, April 25th. Guggenheim began coverage on shares of Satellos Bioscience in a report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Monday. Finally, HC Wainwright boosted their target price on shares of Satellos Bioscience to $11.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $18.00.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.